Cellectar Biosciences (CLRB) Competitors $1.56 -0.05 (-3.11%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CLRB vs. OCUP, MLND, URGN, LFCR, ATYR, FATE, BNTC, PYXS, ACB, and TRVIShould you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Ocuphire Pharma (OCUP), Millendo Therapeutics (MLND), UroGen Pharma (URGN), Lifecore Biomedical (LFCR), Atyr PHARMA (ATYR), Fate Therapeutics (FATE), Benitec Biopharma (BNTC), Pyxis Oncology (PYXS), Aurora Cannabis (ACB), and Trevi Therapeutics (TRVI). These companies are all part of the "medical" sector. Cellectar Biosciences vs. Ocuphire Pharma Millendo Therapeutics UroGen Pharma Lifecore Biomedical Atyr PHARMA Fate Therapeutics Benitec Biopharma Pyxis Oncology Aurora Cannabis Trevi Therapeutics Ocuphire Pharma (NASDAQ:OCUP) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, community ranking, risk, valuation, earnings and dividends. Does the MarketBeat Community believe in OCUP or CLRB? Cellectar Biosciences received 205 more outperform votes than Ocuphire Pharma when rated by MarketBeat users. However, 69.81% of users gave Ocuphire Pharma an outperform vote while only 56.02% of users gave Cellectar Biosciences an outperform vote. CompanyUnderperformOutperformOcuphire PharmaOutperform Votes3769.81% Underperform Votes1630.19% Cellectar BiosciencesOutperform Votes24256.02% Underperform Votes19043.98% Do institutionals and insiders believe in OCUP or CLRB? 15.0% of Ocuphire Pharma shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 8.7% of Ocuphire Pharma shares are owned by insiders. Comparatively, 3.7% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is OCUP or CLRB more profitable? Cellectar Biosciences has a net margin of 0.00% compared to Ocuphire Pharma's net margin of -85.75%. Cellectar Biosciences' return on equity of 0.00% beat Ocuphire Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Ocuphire Pharma-85.75% -30.19% -27.55% Cellectar Biosciences N/A N/A -176.62% Which has more volatility and risk, OCUP or CLRB? Ocuphire Pharma has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500. Do analysts prefer OCUP or CLRB? Ocuphire Pharma presently has a consensus target price of $16.00, suggesting a potential upside of 0.00%. Cellectar Biosciences has a consensus target price of $20.00, suggesting a potential upside of 1,182.05%. Given Cellectar Biosciences' higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Ocuphire Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocuphire Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Cellectar Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to OCUP or CLRB? In the previous week, Cellectar Biosciences had 15 more articles in the media than Ocuphire Pharma. MarketBeat recorded 16 mentions for Cellectar Biosciences and 1 mentions for Ocuphire Pharma. Cellectar Biosciences' average media sentiment score of 0.15 beat Ocuphire Pharma's score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocuphire Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectar Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, OCUP or CLRB? Ocuphire Pharma has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Ocuphire Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcuphire Pharma$16.45M0.00-$9.99M-$0.49N/ACellectar BiosciencesN/AN/A-$42.77M-$2.53-0.62 SummaryOcuphire Pharma and Cellectar Biosciences tied by winning 9 of the 18 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLRB vs. The Competition Export to ExcelMetricCellectar BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.29M$6.45B$5.06B$8.82BDividend YieldN/A8.11%5.18%4.07%P/E Ratio-0.6210.78126.3117.81Price / SalesN/A243.711,178.7474.57Price / CashN/A22.1633.8632.53Price / Book-1.635.474.684.68Net Income-$42.77M$153.61M$119.54M$226.08M7 Day Performance-22.39%-2.00%-1.83%-1.04%1 Month Performance-26.07%-7.46%-3.60%1.04%1 Year Performance-27.10%31.82%31.91%26.28% Cellectar Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLRBCellectar Biosciences2.4949 of 5 stars$1.56-3.1%$20.00+1,182.1%-27.8%$66.44MN/A-0.9110Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageOCUPOcuphire Pharma0.9179 of 5 starsN/A$16.00+∞N/A$30.33M$16.45M-2.3914High Trading VolumeMLNDMillendo TherapeuticsN/A$0.90+3.5%N/A-77.1%$17.11MN/A0.0012Gap UpURGNUroGen Pharma3.78 of 5 stars$11.45+2.6%$48.38+322.5%-7.9%$261.74M$82.71M0.00200LFCRLifecore Biomedical1.5431 of 5 stars$7.48+5.5%$8.00+7.0%+0.7%$261.10M$128.26M93.50690ATYRAtyr PHARMA3.0032 of 5 stars$2.99-1.6%$19.25+543.8%N/A$255.18M$350,000.000.0056FATEFate Therapeutics3.9121 of 5 stars$2.22+1.8%$6.75+204.1%-14.6%$248.29M$63.53M0.00550Analyst UpgradeBNTCBenitec Biopharma2.2948 of 5 stars$10.66+7.9%$22.60+112.0%+202.8%$247.53M$80,000.000.0020Positive NewsPYXSPyxis Oncology1.0428 of 5 stars$3.82-8.2%$9.57+150.6%+165.3%$247.38MN/A0.0060News CoverageGap UpHigh Trading VolumeACBAurora Cannabis0.6391 of 5 stars$4.24+1.4%N/A-11.0%$232.52M$200.35M-5.581,073TRVITrevi Therapeutics3.4144 of 5 stars$2.77-7.7%$7.43+168.2%+113.1%$230.60MN/A0.0020 Related Companies and Tools Related Companies OCUP Alternatives MLND Alternatives URGN Alternatives LFCR Alternatives ATYR Alternatives FATE Alternatives BNTC Alternatives PYXS Alternatives ACB Alternatives TRVI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CLRB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLRB Stock Alerts